The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.

Anaplasma phagocytophilum surface protein AipA and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. AipA proteins and protein fragments or antibodies directed to AipA proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with Anaplasmatacaea. AipA and/or fragments thereof are also used for these purposes in combination with one or both of Asp14 and OmpA proteins and/or fragments thereof which comprise an invasin domain. Homologs of these proteins are also used in the compositions and assays.

Anaplasma phagocytophilum surface protein AipA and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. AipA proteins and protein fragments or antibodies directed to AipA proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with Anaplasmatacaea. AipA and/or fragments thereof are also used for these purposes in combination with one or both of Asp14 and OmpA proteins and/or fragments thereof which comprise an invasin domain. Homologs of these proteins are also used in the compositions and assays.

Rocky Mountain Spotted Fever (RMSF) is a vector borne disease that is caused by Rickettsia rickettsii infection. It is challenging to identify the disease in dogs and other mammals due to the cross-reacting antibodies from non-pathogenic Rickettsia spp. Provided herein are compositions and methods for detection and treatment of Rocky Mountain spotted fever (RMSF). The compositions specifically detect Rickettsia rickettsii and do not cross-react with other Rickettsia species providing rapid and accurate detection and diagnosis of RMSF.

Rocky Mountain Spotted Fever (RMSF) is a vector borne disease that is caused by Rickettsia rickettsii infection. It is challenging to identify the disease in dogs and other mammals due to the cross-reacting antibodies from non-pathogenic Rickettsia spp. Provided herein are compositions and methods for detection and treatment of Rocky Mountain spotted fever (RMSF). The compositions specifically detect Rickettsia rickettsii and do not cross-react with other Rickettsia species providing rapid and accurate detection and diagnosis of RMSF.

Immunoreactive engineered polypeptides are provided. The engineered polypeptides can be used to diagnose or induce an immune response against E. chaffeensis or E. canis.

Immunoreactive engineered polypeptides are provided. The engineered polypeptides can be used to diagnose or induce an immune response against E. chaffeensis or E. canis.

The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.

The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.

The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.